Editorial
Implications of commercial testosterone prescribing for the NHS
BMJ · 14.10.2026 · 395 · e101080
DOI: 10.1136/bmj-2026-101080 ↗Kurz gefasst
Editorial in der Zeitschrift BMJ, online erschienen am 14.10.2026. Verfasst von Stephen L Atkin und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Postgraduate Studies and Research, Royal College of Surgeons in Ireland Medical University of Bahrain, Adliya, Bahrain satkin@rcsi.com. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- School of Postgraduate Studies and Research, Royal College of Surgeons in Ireland Medical University of Bahrain, Adliya, Bahrain satkin@rcsi.com.
- Department of Clinical Biochemistry, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Zitieren
APA
Atkin, S. L., & Kilpatrick, E. S. (2026). Implications of commercial testosterone prescribing for the NHS. BMJ, 395, e101080. https://doi.org/10.1136/bmj-2026-101080
Vancouver
Atkin SL, Kilpatrick ES. Implications of commercial testosterone prescribing for the NHS. BMJ. 2026;395:e101080. doi:10.1136/bmj-2026-101080
BibTeX
@article{Atkin2026,
author = {Atkin, Stephen L and Kilpatrick, Eric S},
title = {Implications of commercial testosterone prescribing for the NHS},
journal = {BMJ},
year = {2026},
volume = {395},
pages = {e101080},
doi = {10.1136/bmj-2026-101080}
}
EUVIMED